Ron DiSantis - Certara Senior Development
| CERT Stock | USD 10.76 0.05 0.47% |
Executive
Ron DiSantis is Senior Development of Certara
| Address | 100 Overlook Center, Princeton, NJ, United States, 08540 |
| Phone | 609 716 7900 |
| Web | https://www.certara.com |
Certara Management Efficiency
Return On Tangible Assets is likely to drop to -0.16 in 2024. Return On Capital Employed is likely to gain to -0.03 in 2024. Total Current Liabilities is likely to drop to about 97 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 1.5 B in 2024Certara's management efficiency ratios could be used to measure how well Certara manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jay Stevens | Privia Health Group | N/A | |
| Jonathan JD | Evolent Health | 56 | |
| John MD | Evolent Health | N/A | |
| Kevin JD | HealthStream | 54 | |
| Christophe Louvion | National Research Corp | 51 | |
| Tia Padia | HealthEquity | N/A | |
| Steve Lindsay | HealthEquity | N/A | |
| Michael JD | HealthStream | 48 | |
| Andy Monnich | National Research Corp | 48 | |
| Jennifer Baron | National Research Corp | N/A | |
| Kamesh Tumsi | HealthEquity | N/A | |
| Kevin OHara | HealthStream | 54 | |
| Eric Beyer | Privia Health Group | N/A | |
| Jason Hahn | National Research Corp | 52 | |
| Vinitha Ramnathan | National Research Corp | N/A | |
| Michael McQuigg | HealthStream | 56 | |
| Brad Bennion | HealthEquity | N/A | |
| Mark Mannion | Evolent Health | N/A | |
| Megan Charko | National Research Corp | N/A | |
| Scott Fenstermacher | HealthStream | 55 | |
| Jessica White | Evolent Health | N/A | |
Management Performance
| Return On Equity | -0.0295 | ||||
| Return On Asset | 0.0059 |
Certara Leadership Team
Elected by the shareholders, the Certara's board of directors comprises two types of representatives: Certara inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Certara. The board's role is to monitor Certara's management team and ensure that shareholders' interests are well served. Certara's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Certara's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Traynor, General VP | ||
| Frederic Bois, Head Advisor | ||
| Robert Aspbury, President Software | ||
| Sheila MBA, Chief Officer | ||
| Ron DiSantis, Senior Development | ||
| Patrick PharmD, President Solutions | ||
| William Feehery, CEO Director | ||
| John III, Chief Officer | ||
| Max Kanevsky, Chief Officer | ||
| Andrew Schemick, Chief Officer | ||
| Rona Anhalt, Chief Officer | ||
| Nicolette Sherman, Chief Officer | ||
| Jaap Mandema, Chief Officer | ||
| Leif Pedersen, President Officer | ||
| Daniel Corcoran, Chief Counsel |
Certara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Certara a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0295 | ||||
| Return On Asset | 0.0059 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 1.8 B | ||||
| Shares Outstanding | 160.99 M | ||||
| Shares Owned By Insiders | 2.59 % | ||||
| Shares Owned By Institutions | 95.67 % | ||||
| Number Of Shares Shorted | 4.95 M | ||||
| Price To Book | 1.64 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Certara Stock Analysis
When running Certara's price analysis, check to measure Certara's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Certara is operating at the current time. Most of Certara's value examination focuses on studying past and present price action to predict the probability of Certara's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Certara's price. Additionally, you may evaluate how the addition of Certara to your portfolios can decrease your overall portfolio volatility.